{"disease":{"id":"hras-mutant-tumor","name":"hras mutant tumor"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02383927","title":"Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"Kura Oncology, Inc.","has_results":true}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}